JP2022522914A5 - - Google Patents
Info
- Publication number
- JP2022522914A5 JP2022522914A5 JP2021510533A JP2021510533A JP2022522914A5 JP 2022522914 A5 JP2022522914 A5 JP 2022522914A5 JP 2021510533 A JP2021510533 A JP 2021510533A JP 2021510533 A JP2021510533 A JP 2021510533A JP 2022522914 A5 JP2022522914 A5 JP 2022522914A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- agent
- cell
- cells
- days
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1807050.8 | 2018-04-30 | ||
| GBGB1807050.8A GB201807050D0 (en) | 2018-04-30 | 2018-04-30 | Medical uses |
| PCT/EP2019/061122 WO2019211310A1 (en) | 2018-04-30 | 2019-04-30 | Medical uses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022522914A JP2022522914A (ja) | 2022-04-21 |
| JPWO2019211310A5 JPWO2019211310A5 (https=) | 2022-05-12 |
| JP2022522914A5 true JP2022522914A5 (https=) | 2022-05-12 |
Family
ID=62494975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510533A Pending JP2022522914A (ja) | 2018-04-30 | 2019-04-30 | 医学的使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210186977A1 (https=) |
| EP (1) | EP3787685A1 (https=) |
| JP (1) | JP2022522914A (https=) |
| KR (1) | KR102908831B1 (https=) |
| CN (1) | CN112399858A (https=) |
| AU (1) | AU2019264457B2 (https=) |
| BR (1) | BR112020022062A2 (https=) |
| CA (1) | CA3097379A1 (https=) |
| GB (1) | GB201807050D0 (https=) |
| WO (1) | WO2019211310A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112168829B (zh) * | 2020-09-24 | 2022-02-15 | 华南理工大学 | 抗病毒药物在制备治疗骨髓增生异常综合征药物中的应用及制得的骨髓增生异常综合征药物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007016450A2 (en) * | 2005-07-29 | 2007-02-08 | Beth Israel Deaconess Medical Center | Methods for treating or preventing reactivation of a latent herpesvirus infection |
| CN101506154B (zh) * | 2006-08-21 | 2015-06-17 | 辛塔制药公司 | 用于治疗增生性疾病的化合物 |
| US20090123442A1 (en) * | 2007-11-09 | 2009-05-14 | Avaris Ab | Expanded nk cells |
| US8877182B2 (en) * | 2009-03-26 | 2014-11-04 | Cellprotect Nordic Pharmaceuticals Ab | Expansion of NK cells |
| US20130011376A1 (en) * | 2009-12-29 | 2013-01-10 | Gamida Cell Ltd. | Methods for Enhancing Natural Killer Cell Proliferation and Activity |
| JP5989016B2 (ja) * | 2011-06-24 | 2016-09-07 | 国立大学法人九州大学 | Ｎｋ細胞の増幅方法 |
| JP6501264B2 (ja) * | 2012-07-24 | 2019-04-17 | アヴァリン ファーマ インク． | エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用 |
| US20180021378A1 (en) * | 2014-12-31 | 2018-01-25 | Anthrogenesis Corporation | Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells |
| KR102416781B1 (ko) * | 2015-08-20 | 2022-07-05 | 고려대학교 산학협력단 | 수두 대상포진 바이러스에 의해 유발되는 질병의 치료 또는 예방용 약학 조성물 |
-
2018
- 2018-04-30 GB GBGB1807050.8A patent/GB201807050D0/en not_active Ceased
-
2019
- 2019-04-30 CN CN201980029357.3A patent/CN112399858A/zh active Pending
- 2019-04-30 KR KR1020207034431A patent/KR102908831B1/ko active Active
- 2019-04-30 US US17/048,702 patent/US20210186977A1/en active Pending
- 2019-04-30 BR BR112020022062-0A patent/BR112020022062A2/pt unknown
- 2019-04-30 EP EP19722058.5A patent/EP3787685A1/en active Pending
- 2019-04-30 AU AU2019264457A patent/AU2019264457B2/en active Active
- 2019-04-30 JP JP2021510533A patent/JP2022522914A/ja active Pending
- 2019-04-30 CA CA3097379A patent/CA3097379A1/en active Pending
- 2019-04-30 WO PCT/EP2019/061122 patent/WO2019211310A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12522570B2 (en) | Toll like receptor modulator compounds | |
| EP3507288B1 (en) | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators | |
| US9358233B2 (en) | Method for treating acute myeloid leukemia | |
| Riese et al. | Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes | |
| AU2006320162B2 (en) | Use of high-dose oxazaphosphorine drugs for treating immune disorders | |
| ES3036762T3 (en) | A modulatable switch for selection of donor modified cells | |
| US20080032989A1 (en) | Method of treating inflammatory diseases using tyroskine kinase inhibitors | |
| JP2020528455A5 (https=) | ||
| CN112804994A (zh) | 治疗骨髓增殖性肿瘤的方法 | |
| TW201513864A (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| Gold et al. | Neuroprotection in Demyelinating Diseases | |
| Li et al. | Haploidentical transplantation with modified post-transplantation cyclophosphamide for patients with primary aplastic anemia: a multicenter experience | |
| JP2013511975A5 (https=) | ||
| EP4424316B1 (en) | Antitumor pharmaceutical composition comprising azvudine and chemotherapeutic agent | |
| JP2022522914A5 (https=) | ||
| AU2014295018A1 (en) | Volasertib in combination with Decitabine for the treatment of acute myeloid leukemia and myelodysplastic syndrome | |
| JPWO2019211310A5 (https=) | ||
| JP2022522914A (ja) | 医学的使用 | |
| JPWO2020157577A5 (https=) | ||
| EP3024488A1 (en) | Volasertib in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome ii | |
| Khaidarov et al. | PHARMACOLOGICAL OVERVIEW OF ACYCLOVIR | |
| Nadeem et al. | Treatment of Multiple Sclerosis | |
| CA1332222C (en) | Pharmaceutical composition for preventing and treating diseases caused by primary immune deficiences | |
| CN116157126A (zh) | 固有免疫激活药物及其用途 | |
| WO2023116397A1 (zh) | 固有免疫激活药物及其用途 |